Bluebird Bio Pauses Trials of Potential Gene Therapy LentiGlobin

Bluebird Bio Pauses Trials of Potential Gene Therapy LentiGlobin

287011

Bluebird Bio Pauses Trials of Potential Gene Therapy LentiGlobin

Bluebird Bio has paused two clinical trials of LentiGlobin, its gene therapy candidate for sickle cell disease (SCD), after learning that a patient who received treatment more than five years ago now has developed acute myeloid leukemia (AML), a type of blood cancer. In line with study protocols, the HGB-206 Phase 1/2 (NCT02140554) and the HGB-210 Phase 3 (NCT04293185) trials will remain suspended temporarily until the company determines if the development of AML is related…

You must be logged in to read/download the full post.